Comprehensive Cancer Center of Wake Forest COOP Research Base

维克森林大学COOP研究基地综合癌症中心

• 批准号: 8520190
• 负责人: EDWARD G SHAW
• 金额: $ 260.64万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-07 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8520190
• 关键词: Area; Behavior Therapy; Biological Factors; Botanicals; Cancer Control; Cancer Prevention Trial; Collaborations; Communities; Community Clinical Oncology Program; Community Practice; Comprehensive Cancer Center; Controlled Clinical Trials; Controlled Study; Development; Diagnosis; Faculty; Fostering; Funding; Goals; Institution; Intervention Studies; Longevity; Longitudinal Studies; Malignant Neoplasms; Minority Groups; Patients; Prevention; Quality of life; Recording of previous events; Reporting; Research; Science; Symptoms; Time; Toxic effect; Training; base; career; forest; innovation; member; survivorship

DESCRIPTION (provided by applicant): This is the third competing renewal application for the Comprehensive Cancer of Wake Forest Community Clinical Oncology Program Research Base (WF Research Base), which was initially funded in 1999. Specific Aims for the next five years include the following: Specific Aim 1: To conduct cancer control studies that impact community oncology practice by enhancing patients' quality of life through prevention and treatment of symptoms across the survivorship lifespan (i.e., from diagnosis to the end of therapy and from the end of therapy forward) in the following thematic areas: botanical/natural products and other integrative approaches; conventional pharmacologic agents; behavioral interventions; non-intervention studies (e.g., correlative science and observational/longitudinal studies; and cancer prevention trials). Specific Aim 2: To use correlative science in conjunction with WF Research Base cancer control studies to understand the basic mechanisms by which symptoms and toxicities of cancer and its treatments occur. Specific Aim 3: To develop and utilize innovative, culturally-tailored strategies to increase the participation of racial/ethnic minorities traditionaly underrepresented in cancer control studies. Specific Aim 4: To foster active collaboration and offer training in the development, conduct, and reporting of cancer control clinical trials for CCOP/MBCCOP professionals, early career faculty, and trainees. The current application is the strongest competing renewal application for the WF Research Base in our 12 year history. Over time, we have increased the number of studies, accruals, and affiliated communities and institutions. The diversity, depth and breadth of our four open and four soon-to-open studies and 20 developing concepts is evidence of the unique and diverse menu of studies we provide, and the important niche we fill for our participating CCOPs, MBCCOPs and Prevention Members.

DESCRIPTION (provided by applicant): This is the third competing renewal application for the Comprehensive Cancer of Wake Forest Community Clinical Oncology Program Research Base (WF Research Base), which was initially funded in 1999. Specific Aims for the next five years include the following: Specific Aim 1: To conduct cancer control studies that impact community oncology practice by enhancing patients' quality of life through prevention and treatment of symptoms across the survivorship lifespan (i.e., from diagnosis to the end of在以下主题领域的治疗和疗法末期开始：植物/天然产品和其他综合方法；常规药理学剂；行为干预；非干预研究（例如，相关科学与观察/纵向研究；以及癌症预防试验）。具体目的2：将相关科学与WF研究基础癌症控制研究结合使用，以了解癌症及其治疗的症状和毒性的基本机制。特定目的3：开发和利用创新的，文化定制的策略，以增加传统中人数不足在癌症控制研究中的种族/少数民族的参与。特定目标4：为CCOP/MBCCOP专业人员，早期职业教师和受训者的癌症控制临床试验的开发，进行和报告培养积极合作并提供培训。当前的申请是我们12年历史上WF研究基础的最强竞争续订应用程序。随着时间的流逝，我们增加了研究，应计和附属社区和机构的数量。我们的四个开放和四个即将开放的研究以及20个发展概念的多样性，深度和广度是我们提供的独特而多样化的研究菜单的证据，以及我们为参与的CCOPS，MBCCOPS和预防成员填写的重要利基。

项目成果

A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia.

• DOI: 10.1016/j.suponc.2011.10.005
• 发表时间: 2012-09
• 期刊: The journal of supportive oncology
• 作者: High, Kevin P;Case, Doug;Hurd, David;Powell, Bayard;Lesser, Glenn;Falsey, Ann R;Siegel, Robert;Metzner-Sadurski, Joanna;Krauss, John C;Chinnasami, Bernard;Sanders, George;Rousey, Steven;Shaw, Edward G
• 通讯作者: Shaw, Edward G

Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood.

• DOI: 10.1007/s11060-012-0901-9
• 发表时间: 2012-09
• 期刊: JOURNAL OF NEURO-ONCOLOGY
• 影响因子: 3.9
• 作者: Attia, Albert;Rapp, Stephen R.;Case, L. Doug;D'Agostino, Ralph;Lesser, Glenn;Naughton, Michelle;McMullen, Kevin;Rosdhal, Robin;Shaw, Edward G.
• 通讯作者: Shaw, Edward G.

Symptom clusters in patients with newly-diagnosed brain tumors.

新诊断脑肿瘤患者的症状群。

• 发表时间: 2007
• 期刊: The journal of supportive oncology
• 作者: GleasonJr,JohnF;Case,Douglas;Rapp,StephenR;Ip,Edward;Naughton,Michelle;ButlerJr,JeromeM;McMullen,Kevin;Stieber,Volker;Saconn,Paul;Shaw,EdwardG
• 通讯作者: Shaw,EdwardG

The management of radiation-induced brain injury.

• DOI: 10.1007/0-387-25354-8_2
• 发表时间: 2006
• 期刊: Cancer treatment and research
• 作者: E. Shaw;M. Robbins

A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.

沙利度胺和丙卡巴肼治疗复发性或进行性恶性神经胶质瘤成人患者的 II 期试验。

• DOI: 10.1007/s11060-011-0698-y
• 发表时间: 2012
• 期刊: Journal of neuro-oncology
• 影响因子: 3.9
• 作者: Ruiz,Jimmy;Case,Doug;Enevold,Gina;Rosdhal,Robin;Tatter,StephenB;Ellis,ThomasL;McQuellon,RichardP;McMullen,KevinP;Stieber,VolkerW;Shaw,EdwardG;Lesser,GlennJ
• 通讯作者: Lesser,GlennJ